Last reviewed · How we verify
Panax notoginseng saponins
Panax notoginseng saponins, marketed by Yunling Zhang, is a currently available drug with a key composition patent expiring in 2028. The drug's market position and competitive advantage are not specified, but the patent expiry will likely impact revenue streams post-2028. Without detailed trial results or revenue data, the primary risk remains the potential for increased competition following patent expiration.
At a glance
| Generic name | Panax notoginseng saponins |
|---|---|
| Also known as | Xueshuantong injections, XUESAITONG Injection, Xueshuantong injection |
| Sponsor | Yunling Zhang |
| Modality | Small molecule |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- Clinical Study and Molecular Mechanism of Xuesaitong Soft Capsule in the Treatment of Acute Coronary Syndrome (PHASE1, PHASE2)
- Clinical Study on the Intervention of Xuesaitong Soft Capsules in Post-Intervention Patients with Acute Coronary Syndrome and Clinical Research Protocol (PHASE3)
- Post-marketing Safety Surveillance of Xueshuantong-Injection : a Registry Study
- The Effect of Farlong® NotoGinseng™ (Ginseng Plus®) on Cholesterol and Blood Pressure (PHASE2)
- Heat-clearing and Blood-activating Chinese Medicinal Components in Acute Cerebral Infarction (NA)
- Efficacy and Safety of Xuesaitong Soft Capsule for Coronary Heart Disease Unstable Angina (PHASE2)
- Clinical Study on the Treatment of Hypertensive Intracerebral Hemorrhage With Panax Notoginseng Saponin (PHASE4)
- Clinical Application and Basic Study of Medicinal Fractions-based Herbal Combinations (NA)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Panax notoginseng saponins CI brief — competitive landscape report
- Panax notoginseng saponins updates RSS · CI watch RSS
- Yunling Zhang portfolio CI